JP2004509902A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509902A5
JP2004509902A5 JP2002529162A JP2002529162A JP2004509902A5 JP 2004509902 A5 JP2004509902 A5 JP 2004509902A5 JP 2002529162 A JP2002529162 A JP 2002529162A JP 2002529162 A JP2002529162 A JP 2002529162A JP 2004509902 A5 JP2004509902 A5 JP 2004509902A5
Authority
JP
Japan
Prior art keywords
methyl
glucopyranosyl
tri
sulfonate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002529162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509902A (ja
JP5016778B2 (ja
Filing date
Publication date
Priority claimed from FR0012094A external-priority patent/FR2814463B1/fr
Application filed filed Critical
Publication of JP2004509902A publication Critical patent/JP2004509902A/ja
Publication of JP2004509902A5 publication Critical patent/JP2004509902A5/ja
Application granted granted Critical
Publication of JP5016778B2 publication Critical patent/JP5016778B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002529162A 2000-09-22 2001-09-20 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド Expired - Fee Related JP5016778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/12094 2000-09-22
FR0012094A FR2814463B1 (fr) 2000-09-22 2000-09-22 Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
PCT/FR2001/002918 WO2002024754A1 (fr) 2000-09-22 2001-09-20 Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012027377A Division JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Publications (3)

Publication Number Publication Date
JP2004509902A JP2004509902A (ja) 2004-04-02
JP2004509902A5 true JP2004509902A5 (cg-RX-API-DMAC7.html) 2012-03-29
JP5016778B2 JP5016778B2 (ja) 2012-09-05

Family

ID=8854579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002529162A Expired - Fee Related JP5016778B2 (ja) 2000-09-22 2001-09-20 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド
JP2012027377A Pending JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012027377A Pending JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Country Status (39)

Country Link
US (3) US6844329B2 (cg-RX-API-DMAC7.html)
EP (1) EP1322673B1 (cg-RX-API-DMAC7.html)
JP (2) JP5016778B2 (cg-RX-API-DMAC7.html)
KR (2) KR100891388B1 (cg-RX-API-DMAC7.html)
CN (1) CN1235914C (cg-RX-API-DMAC7.html)
AR (1) AR030774A1 (cg-RX-API-DMAC7.html)
AT (1) ATE374215T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001291960C1 (cg-RX-API-DMAC7.html)
BG (1) BG66191B1 (cg-RX-API-DMAC7.html)
BR (1) BR0114007A (cg-RX-API-DMAC7.html)
CA (1) CA2418815C (cg-RX-API-DMAC7.html)
CY (1) CY1108076T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300856B6 (cg-RX-API-DMAC7.html)
DE (1) DE60130669T2 (cg-RX-API-DMAC7.html)
DK (1) DK1322673T3 (cg-RX-API-DMAC7.html)
EA (1) EA005133B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034514A (cg-RX-API-DMAC7.html)
EE (1) EE05202B1 (cg-RX-API-DMAC7.html)
ES (1) ES2292625T3 (cg-RX-API-DMAC7.html)
FR (1) FR2814463B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20053616B (cg-RX-API-DMAC7.html)
HR (1) HRP20030219B1 (cg-RX-API-DMAC7.html)
HU (2) HUP0303551A3 (cg-RX-API-DMAC7.html)
IL (2) IL154848A0 (cg-RX-API-DMAC7.html)
IS (1) IS2550B (cg-RX-API-DMAC7.html)
ME (2) ME00080B (cg-RX-API-DMAC7.html)
MX (1) MXPA03002483A (cg-RX-API-DMAC7.html)
NO (2) NO332905B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524472A (cg-RX-API-DMAC7.html)
PE (1) PE20020471A1 (cg-RX-API-DMAC7.html)
PL (1) PL206727B1 (cg-RX-API-DMAC7.html)
PT (1) PT1322673E (cg-RX-API-DMAC7.html)
RS (1) RS50730B (cg-RX-API-DMAC7.html)
SI (1) SI1322673T1 (cg-RX-API-DMAC7.html)
SK (2) SK287218B6 (cg-RX-API-DMAC7.html)
TW (1) TWI308153B (cg-RX-API-DMAC7.html)
UA (1) UA79736C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002024754A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301692B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
PL1991271T3 (pl) * 2005-10-10 2011-08-31 Merck Sharp & Dohme Podwójne inhibitory antykoagulacyjne -przeciwzakrzepowe zawierające znacznik biotynowy
ES2362011T3 (es) * 2005-10-10 2011-06-27 N.V. Organon Inhibidores duales antitrombóticos anticoagulantes que comprenden una marca de biotina.
CN1317035C (zh) * 2005-10-24 2007-05-23 天津大学 基于酰肼基的微粒表面多重生物功能因子组装方法
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
AU2009335709A1 (en) 2008-12-19 2011-07-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
FR2952935B1 (fr) 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
WO2011073408A2 (en) 2009-12-18 2011-06-23 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CZ302510B6 (cs) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace sloucenin s karboxylovou skupinou pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
CZ302669B6 (cs) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace aminosloucenin pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
ES2852899T3 (es) 2010-03-31 2021-09-14 Supernus Pharmaceuticals Inc Formulaciones estabilizadas de molindona
EP2614089A1 (fr) * 2010-09-10 2013-07-17 Sanofi-Aventis Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
FR2964660B1 (fr) * 2010-09-10 2012-09-28 Sanofi Aventis Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
ES2560467T3 (es) * 2011-06-17 2016-02-19 Carbomimetics Pentasacáridos sintéticos que tienen vida media corta y alta actividad
AU2013344920A1 (en) * 2012-11-13 2015-04-30 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
EP3529205B1 (en) 2016-10-21 2022-06-15 The United States of America, as represented by the Secretary, Department of Health and Human Services Molecular nanotags
CN108976318B (zh) * 2017-06-01 2021-03-30 首都医科大学 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
JP2022540849A (ja) 2019-07-09 2022-09-20 オプティムヴィア、エルエルシー 抗凝固性多糖類の合成方法
CN114556685B (zh) * 2019-10-17 2024-04-02 株式会社自动网络技术研究所 布线模块
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)
WO2024191684A1 (en) 2023-03-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis c virus ribonucleic acid from whole blood using reverse transcription loop-mediated isothermal amplification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
CA2305619C (en) 1998-07-31 2008-05-20 Seikagaku Corporation Novel glycosaminoglycan and pharmaceutical composition using the same as active ingredient
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Similar Documents

Publication Publication Date Title
JP2004509902A5 (cg-RX-API-DMAC7.html)
JP2510925B2 (ja) ガラクトサミン−ウロン酸基本(モチ―フ)を含むオリゴ糖類及びそれらの生物学的用途
RU2167163C2 (ru) Синтетические полисахариды, способ их получения и содержащая их фармацевтическая композиция
JP7085631B2 (ja) プレシオモナス・シゲロイデスo51血清型o-抗原オリゴ糖の化学合成方法
JPH05194602A (ja) 硫酸化グリコサミノグリカノイド誘導体
Jacquinet et al. Stereocontrolled preparation of biotinylated chondroitin sulfate E di-, tetra-, and hexasaccharide conjugates
FR2773804A1 (fr) Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
Toepfer et al. An efficient synthesis of the Lewis A (Lea) antigen pentasaccharide moiety
JP2021505706A (ja) ヘリコバクタ‐・ピロリリポ多糖の外部コアの八炭糖の調製方法
FR2773801A1 (fr) Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
AU2010234779A1 (en) Heparan sulfate synthesis
Bozo et al. Synthesis of 4-cyanophenyl and 4-nitrophenyl 1, 5-dithio-l-and-d-arabinopyranosides possessing antithrombotic activity
JP5981520B2 (ja) 配糖体の2−硫酸化方法
Sakairi et al. Modification of cyclodextrins by insertion of a heterogeneous sugar unit into their skeletons. Synthesis of 2-amino-2-deoxy-β-cyclodextrin from α-cyclodextrin
Stahl et al. Synthesis of Sulfated Lex‐Trisaccharides
Bock et al. Derivatives of methyl β-lactoside as substrates for and inhibitors of β-D-galactosidase from E. coli
Hermans et al. Benzyl-2, 4-Diacetamido-2, 4, 6-Tri-Deoxy-α (β)-D-Galactopyranoside
JPH10502093A (ja) レジオ選択的硫酸化
Ghosh et al. Common protection–deprotection strategies in carbohydrate synthesis
WO1993024506A1 (en) IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISC AND LacNAc COMPOUNDS
JP5089998B2 (ja) 4−硫酸化ヒアルロン酸
Abad-Romero et al. Synthesis of regioselectively sulfated xylodextrins and crystal structure of sodium methyl β-d-xylopyranoside 4-O-sulfate hemihydrate
Mukherjee et al. Towards the complete synthetic O-antigen of Vibrio cholerae O1, serotype inaba: improved synthesis of the conjugation-ready upstream terminal hexasaccharide determinant
Hou et al. Synthesis of 8-azidooctyl glycoside derivatives of the O-chain repeating unit of Escherichia coli O9a lipopolysaccharide and a methylated analog
JPH02292295A (ja) エトポシドの製造方法